Articles dans des revues avec comité de lecture (24)
  1. 13. Lapouge, G., Kass, Y. K., Vokaer, B., Achouri, Y., Michaux, C., Sotiropoulou, P., & Blanpain, C. (2011). Identifying the cellular origin of squamous skin tumors. Proceedings of the National Academy of Sciences of the United States of America, 108(18), 7431-7436. doi:10.1073/pnas.1012720108
  2. 14. Kass, Y. K., Lapouge, G., Van Keymeulen, A., & Blanpain, C. (2010). Identification des cellules à l'origine du carcinome basocellulaire. MS. Médecine sciences, 26(12), 1020-1022. doi:10.1051/medsci/201026121020
  3. 15. Sotiropoulou, P., Candi, A., Mascré, G., De Clercq, S., Kass, Y. K., Lapouge, G., Dahl, E., Semeraro, C., Denecker, G., Marine, J.-C., & Blanpain, C. (2010). Bcl-2 and accelerated DNA repair mediates resistance of hair follicle bulge stem cells to DNA-damage-induced cell death. Nature cell biology, 12(6), 572-582. doi:10.1038/ncb2059
  4. 16. Kass, Y. K., Van Keymeulen, A., Lapouge, G., Beck, B., Michaux, C., Achouri, Y., Sotiropoulou, P., & Blanpain, C. (2010). Identification of the cell lineage at the origin of basal cell carcinoma. Nature cell biology. doi:10.1038/ncb2031
  5. 17. Marcias, G., Erdmann, E., Lapouge, G., Siebert, C., Barthélémy, P., Duclos, B., Bergerat, J.-P., Céraline, J., & Kurtz, J.-E. (2010). Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line. Human mutation, 31(1), 74-80. doi:10.1002/humu.21138
  6. 18. Bondue, A., Lapouge, G., Paulissen, C., Semeraro, C., Iacovino, M., Kyba, M., & Blanpain, C. (2008). Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell stem cell, 3(1), 69-84. doi:10.1016/j.stem.2008.06.009
  7. 19. Lapouge, G., Marcias, G., Erdmann, E., Kessler, P., Cruchant, M., Serra, S., Bergerat, J.-P., & Céraline, J. (2008). Specific properties of a C-terminal truncated androgen receptor detected in hormone refractory prostate cancer. Advances in experimental medicine and biology, 617, 529-534. doi:10.1007/978-0-387-69080-3_53
  8. 20. Lapouge, G., Erdmann, E., Marcias, G., Jagla, M., Monge, A., Kessler, P., Serra, S., Lang, H., Jacqmin, D., Bergerat, J.-P., & Céraline, J. (2007). Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation--a new paradigm for cooperation among prostate tumor cells. International journal of cancer, 121(6), 1238-1244. doi:10.1002/ijc.22830
  9. 21. Jagla, M., Fève, M., Kessler, P., Lapouge, G., Erdmann, E., Serra, S., Bergerat, J.-P., & Céraline, J. (2007). A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology, 148(9), 4334-4343. doi:10.1210/en.2007-0446
  10. 22. Monge, A., Jagla, M., Lapouge, G., Sasorith, S., Cruchant, M., Wurtz, J.-M., Jacqmin, D., Bergerat, J.-P., & Céraline, J. (2006). Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer. Cellular and molecular life sciences, 63(4), 487-497. doi:10.1007/s00018-005-5471-y
  11. 23. Lapouge, G., Millon, R., Muller, D., Abecassis, J., Eber, M., Bergerat, J.-P., & Klein-Soyer, C. (2005). Cisplatin-induced genes as potential markers for thyroid cancer. Cellular and molecular life sciences, 62(1), 53-64. doi:10.1007/s00018-004-4329-z
  12. 24. Deplanque, G., Céraline, J., Lapouge, G., Dufour, P., Bergerat, J.-P., & Klein-Soyer, C. (2004). Conflicting effects of caffeine on apoptosis and clonogenic survival of human K1 thyroid carcinoma cell lines with different p53 status after exposure to cisplatin or UVc irradiation. Biochemical and biophysical research communications, 314(4), 1100-1106.
    13. << Précédent 1 2 3 Suivant >>